₹ 621.16 Cr
2.28%
BSE Healthcare TRI
INF251K01VD9
1000.0
1000.0
500
Mr. Sanjay Chawla
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| Baroda BNP Paribas Health and Wellness Fund Regular IDCWPayout | - | - | - |
| Benchmark | - | - | - |
Equity
Debt
Others
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 9.25 |
| MANKIND PHARMA LIMITED EQ NEW FV RE. 1/- | 7.29 |
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 7.05 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 6.18 |
| MAX HEALTHCARE INSTITUTE LIMITED EQ | 5.54 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 5.38 |
| ASTER DM HEALTHCARE LIMITED EQ | 4.91 |
| Clearing Corporation of India Ltd | 4.73 |
| ABBOTT INDIA LIMITED EQ | 4.57 |
| ASTRAZENECA PHARMA INDIA LIMITED EQ NEW FV RS.2/- | 4.0 |
| Sector | Holdings (%) |
|---|---|
| Healthcare | 91.36 |
| Financial Services | 2.76 |
| Consumer Services | 1.41 |